Stock SUCAMPO PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Sucampo Pharmaceuticals, Inc.

Equities

US8649091068

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
SUCAMPO PHARMACEUTICALS, INC. Former SEC Attorney Willie Briscoe Investigates Sale to Mallinckrodt plc
BU
Wall Street slips on tech sector weakness
RE
Mallinckrodt : to buy Sucampo for about $840 million
RE
Sucampo Pharmaceuticals Announces its Participation at the Global Mizuho Investor Conference
GL
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 29th Annual Piper Jaffray Healthcare Conference
GL
Sucampo to Host 2017 R&D Day on November 16 in New York
GL
Sucampo Reports Third Quarter 2017 Financial Results
GL
Sucampo Announces Third Quarter 2017 Earnings Call
GL
Sucampo Pharmaceuticals Announces FDA Acceptance of sNDA for AMITIZA in Children with Pediatric Functional Constipation, with Priority Review Designation
GL
Sucampo Pharmaceuticals Announces Presentation at Deutsche Bank’s 25th Annual Leveraged Finance Conference
GL
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2017 Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
GL
Sucampo Pharmaceuticals Appoints Alex Driggs as General Counsel
GL
Sucampo Pharmaceuticals : Cancer Prevention Pharmaceuticals Receives $9.5 Million in Additional Funding from Sucampo Following Phase 3 Trial Progress
BU
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2017 Wells Fargo Healthcare Conference
GL
Sucampo Pharmaceuticals : Study Results Published in The Lancet Demonstrate Safety and Efficacy of Intrathecal VTS-270 in Niemann-Pick Disease Type C1
PU
Sucampo Pharmaceuticals : Drug Makers Stock Performance Review -- DURECT, Sucampo Pharma, Apricus Biosciences, and MEI Pharma
PR
Sucampo Reports Second Quarter 2017 Financial Results
GL
Sucampo Announces Second Quarter 2017 Earnings Call
GL
Dr. Karen Smith Joins Sucampo’s Board of Directors
GL
Sucampo Pharmaceuticals Announces Issuance of New Patent for VTS-270
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News Sucampo Pharmaceuticals, Inc.